Innovation in Cell Therapy: Bracco Imaging Forms Strategic Partnership with CellBri

We’re proud to announce a new partnership between Bracco Imaging Medical Technologies (Shanghai) and Shenzhen Cellbri Bio-Innovation Technology, aimed at transforming CAR-T cell therapy manufacturing — one of the most promising areas in personalized cancer treatment.

At the heart of this collaboration is the development of an automated system for T cell selection and activation, powered by a new technology called BACSA (Buoyancy-Activated Cell Sorting and Activation). In simple terms, we use specially formulated gas-filled microbubbles to make target cells float and separate from others — a precise, magnet-free approach that challenges conventional methods.

Bracco contributes its smart proprietary microbubble technology, long used in diagnostic ultrasound, now newly designed for in vitro cell processing (outside the human body). Cellbri will integrate this into its Gentle Flex™ platform, creating a fully automated, closed, and scalable solution tailored to meet the demands of the Chinese market.

The benefit? An alternative to traditional magnetic separation — designed to support biotech companies in delivering life-saving therapies faster and more efficiently.

With this partnership, we reaffirm our commitment to impactful innovation with one clear purpose: to improve people’s lives through smarter, safer, and more accessible healthcare solutions.